Stratos Wealth Partners LTD. decreased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 6.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 262,752 shares of the biopharmaceutical company's stock after selling 18,774 shares during the quarter. Stratos Wealth Partners LTD.'s holdings in Pfizer were worth $6,658,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Clarity Asset Management Inc. acquired a new stake in Pfizer in the 4th quarter worth about $27,000. Gould Capital LLC raised its position in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares in the last quarter. North Capital Inc. acquired a new position in shares of Pfizer in the 1st quarter valued at approximately $28,000. Bernard Wealth Management Corp. acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $30,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Trading Up 0.8%
PFE traded up $0.21 during trading on Thursday, reaching $25.77. 39,477,537 shares of the company's stock were exchanged, compared to its average volume of 41,842,555. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $146.49 billion, a PE ratio of 18.67, a price-to-earnings-growth ratio of 0.93 and a beta of 0.58. The firm has a fifty day moving average price of $23.82 and a two-hundred day moving average price of $24.82.
Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the firm posted $0.82 EPS. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.68%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is currently 124.64%.
Analysts Set New Price Targets
Several equities analysts have recently commented on PFE shares. Leerink Partners dropped their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research report on Wednesday, April 30th. Bank of America boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. HSBC decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. TD Cowen decreased their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. Finally, Morgan Stanley lifted their price target on shares of Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and a consensus target price of $28.55.
View Our Latest Stock Report on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
